Ocular Therapeutix™ to Participate in December Investor and Scientific ConferencesGlobeNewsWire • 11/26/24
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/14/24
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIVGlobeNewsWire • 11/13/24
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024GlobeNewsWire • 11/06/24
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMDGlobeNewsWire • 10/15/24
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?Zacks Investment Research • 10/14/24
Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To InvestorsSeeking Alpha • 10/11/24
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/09/24
Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?Zacks Investment Research • 08/09/24
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 08/09/24
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/07/24
Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024GlobeNewsWire • 07/31/24
Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD StudyGlobeNewsWire • 07/30/24
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific MeetingGlobeNewsWire • 07/10/24
This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For ThursdayBenzinga • 06/20/24
Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR StudyGlobeNewsWire • 06/13/24